143 related articles for article (PubMed ID: 38779875)
21. The Impact of Metabolic Bariatric Surgery on Cardiovascular Diseases in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease.
Esparham A; Shoar S; Mehri A; Khorgami Z; Modukuru VR
Obes Surg; 2024 Jul; 34(7):2338-2346. PubMed ID: 38662250
[TBL] [Abstract][Full Text] [Related]
22. Prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) in a middle-aged population with overweight and normal liver enzymes, and diagnostic accuracy of noninvasive proxies.
van Son KC; Te Nijenhuis-Noort LC; Boone SC; Mook-Kanamori DO; Holleboom AG; Roos PR; Lamb HJ; Alblas G; Coenraad MJ; Rosendaal FR; de Mutsert R; Tushuizen ME
Medicine (Baltimore); 2024 Jan; 103(1):e34934. PubMed ID: 38181294
[TBL] [Abstract][Full Text] [Related]
23. Prevalence, proportions of elevated liver enzyme levels, and long-term cardiometabolic mortality of patients with metabolic dysfunction-associated steatotic liver disease.
Chen YT; Chen TI; Yin SC; Huang CW; Huang JF; Lu SN; Yeh ML; Huang CF; Dai CY; Chen YW; Chuang WL; Yu ML; Lee MH
J Gastroenterol Hepatol; 2024 May; ():. PubMed ID: 38725327
[TBL] [Abstract][Full Text] [Related]
24. Cognitive dysfunction in early experimental metabolic dysfunction-associated steatotic liver disease is associated with systemic inflammation and neuroinflammation.
Kjærgaard K; Daugaard Mikkelsen AC; Landau AM; Eriksen PL; Hamilton-Dutoit S; Magnusson NE; Thomsen MB; Chen F; Vilstrup H; Mookerjee RP; Bay-Richter C; Thomsen KL
JHEP Rep; 2024 Mar; 6(3):100992. PubMed ID: 38415019
[TBL] [Abstract][Full Text] [Related]
25. Associations between serum ferritin baselines and trajectories and the incidence of metabolic dysfunction-associated steatotic liver disease: a prospective cohort study.
Song Z; Miao X; Xie X; Tang G; Deng J; Hu M; Liu S; Leng S
Lipids Health Dis; 2024 May; 23(1):141. PubMed ID: 38760825
[TBL] [Abstract][Full Text] [Related]
26. Steatotic liver disease predicts cardiovascular disease and advanced liver fibrosis: A community-dwelling cohort study with 20-year follow-up.
Choe HJ; Moon JH; Kim W; Koo BK; Cho NH
Metabolism; 2024 Apr; 153():155800. PubMed ID: 38266957
[TBL] [Abstract][Full Text] [Related]
27. The association of metabolic dysfunction-associated steatotic liver disease (MASLD) with the risk of myocardial infarction: a systematic review and meta-analysis.
Lv Q; Zhao H
Ann Med; 2024 Dec; 56(1):2306192. PubMed ID: 38253023
[No Abstract] [Full Text] [Related]
28. Does Therapy with Glucagon-like Peptide 1 Receptor Agonists Have an Effect on Biochemical Markers of Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD)? Pleiotropic Metabolic Effect of Novel Antidiabetic Drugs in Patients with Diabetes-Interventional Study.
Hachuła M; Kosowski M; Basiak M; Okopień B
Pharmaceuticals (Basel); 2023 Aug; 16(9):. PubMed ID: 37764998
[TBL] [Abstract][Full Text] [Related]
29. Adipocytokines as Predictors of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Development in Type 2 Diabetes Mellitus Patients.
Fajkić A; Jahić R; Hadžović-Džuvo A; Lepara O
Cureus; 2024 Mar; 16(3):e55673. PubMed ID: 38455340
[TBL] [Abstract][Full Text] [Related]
30. Blood glucose control and metabolic dysfunction-associated steatotic liver disease in people with type 1 diabetes.
Della Pepa G; Lupoli R; Masulli M; Boccia R; De Angelis R; Gianfrancesco S; Piccolo R; Rainone C; Rivellese AA; Annuzzi G; Bozzetto L
J Endocrinol Invest; 2024 Mar; ():. PubMed ID: 38498227
[TBL] [Abstract][Full Text] [Related]
31. Association between the peripheral neutrophil-to-lymphocyte ratio and metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes.
Zhu N; Song Y; Zhang C; Wang K; Han J
Front Med (Lausanne); 2023; 10():1294425. PubMed ID: 38020132
[TBL] [Abstract][Full Text] [Related]
32. Exploring the landscape of steatotic liver disease in the general US population.
Ciardullo S; Carbone M; Invernizzi P; Perseghin G
Liver Int; 2023 Nov; 43(11):2425-2433. PubMed ID: 37592856
[TBL] [Abstract][Full Text] [Related]
33. The Multicomponent Medicinal Product Hepar Compositum Reduces Hepatic Inflammation and Fibrosis in a Streptozotocin- and High-Fat Diet-Induced Model of Metabolic Dysfunction-Associated Steatotic Liver Disease/Metabolic Dysfunction-Associated Steatohepatitis.
Burmeister Y; Weyer K; Dörre A; Seilheimer B
Biomedicines; 2023 Dec; 11(12):. PubMed ID: 38137437
[TBL] [Abstract][Full Text] [Related]
34. The systemic inflammation response index as a risk factor for hepatic fibrosis and long-term mortality among individuals with metabolic dysfunction-associated steatotic liver disease.
Yin Y; Zhu W; Xu Q
Nutr Metab Cardiovasc Dis; 2024 May; ():. PubMed ID: 38866613
[TBL] [Abstract][Full Text] [Related]
35. Mitochondrial Quality Control: Its Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
Shin S; Kim J; Lee JY; Kim J; Oh CM
J Obes Metab Syndr; 2023 Dec; 32(4):289-302. PubMed ID: 38049180
[TBL] [Abstract][Full Text] [Related]
36. Intrapancreatic fat deposition is unrelated to liver steatosis in metabolic dysfunction-associated steatotic liver disease.
Mak AL; Wassenaar N; van Dijk AM; Troelstra M; Houttu V; van Son K; Driessen S; Zwirs D; van den Berg-Faay S; Shumbayawonda E; Runge J; Doukas M; Verheij J; Beuers U; Nieuwdorp M; Cahen DL; Nederveen A; Gurney-Champion O; Holleboom A
JHEP Rep; 2024 Mar; 6(3):100998. PubMed ID: 38379586
[TBL] [Abstract][Full Text] [Related]
37. Metabolic-Dysfunction-Associated Steatotic Liver Disease-Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments.
Yanai H; Adachi H; Hakoshima M; Iida S; Katsuyama H
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895151
[TBL] [Abstract][Full Text] [Related]
38. Increased risk of chronic kidney disease and mortality in a cohort of people diagnosed with metabolic dysfunction associated steatotic liver disease with hepatic fibrosis.
Gurun M; Brennan P; Handjiev S; Khatib A; Leith D; Dillon JF; Byrne CJ
PLoS One; 2024; 19(4):e0299507. PubMed ID: 38625981
[TBL] [Abstract][Full Text] [Related]
39. Steatotic liver disease-associated all-cause/cause-specific mortality in the United States.
Kim D; Wijarnpreecha K; Cholankeril G; Ahmed A
Aliment Pharmacol Ther; 2024 Jul; 60(1):33-42. PubMed ID: 38649335
[TBL] [Abstract][Full Text] [Related]
40. Metabolic dysfunction-associated steatotic liver disease criteria may underestimate the number of lean female nonalcoholic fatty liver disease patients with significant liver fibrosis.
Kobayashi N; Tada T; Nishimura T; Matono T; Yuri Y; Takashima T; Aizawa N; Ikeda N; Fukunishi S; Hashimoto M; Ohyanagi M; Enomoto H; Iijima H
Hepatol Res; 2024 May; 54(5):429-438. PubMed ID: 38015179
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
